RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.
Stocks · News reference
8-K filing — Contineum Therapeutics, Inc. (CTNM)
Filed: 2026-07-30 AccNo: 0001628280-26-051051 Size: 259 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Contineum Therapeutics shares are trading lower after the company reported its Q2 financial results. The company announced a workforce reduction.
Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain
Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate